HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Methyl Aminolevulinate

HCID 157922
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
33320-16-0
Standard SMILES
COC(=O)CCC(=O)CN
InChIKey
YUUAYBAIHCDHHD-UHFFFAOYSA-N
Molecular formula
C6H11NO3
Average molar mass
145.16 g/mol
Monoisotopic mass
145.07389321

Overview

Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumulation of protoporphyrin IX in the skin lesions to which the cream has been applied. Subsequent illumination with red light results in the generation of toxic singlet oxygen that destroys cell membranes and thereby kills the tumour cells. It has a role as an antineoplastic agent, a photosensitizing agent, a dermatologic drug and a prodrug. It is functionally related to a 5-aminolevulinic acid.

Names & identifiers

Preferred name
Methyl Aminolevulinate
IUPAC
methyl 5-amino-4-oxopentanoate
English name
D-Aminolevulinicacidmethylesterhydrochloride
Molecular formula
C6H12ClNO3
Molecular weight
181.61738

Names & synonyms

Methyl aminolevulinatemethyl 5-amino-4-oxopentanoate33320-16-0methyl 5-aminolevulinate5-Aminolevulinic acid methyl estermethyl aminolaevulinatemethyl delta-aminolevulinateMAOP cpdMethylaminolevulinatePentanoic acid, 5-amino-4-oxo-, methyl ester585NM85KYMMethyl-5-aminolevulinate
Show more names
D-AminolevulinicacidmethylesterHCl
DTXSID3048570CHEBI:724125RefChem:157787DTXCID4028202MetvixAminolevulinic acid methyl esterNCGC00018251-03UNII-585NM85KYM

Database identifiers

CAS
33320-16-0
PubChem CID
157922
DTXSID
DTXSID3048570
ChEMBL
CHEMBL1096562
ChEBI
CHEBI:724125
UNII
585NM85KYM
Nikkaji
J313.797J

Properties

Computed structural propertiesFilling in

XLogP
-1
Topological polar surface area
69.4 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
4
Rotatable bonds
5
Heavy atoms
10
Formal charge
0
Complexity
133

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
LogP-1.2
Solubility · 2 items

Freely soluble

2.20e+02 g/L

Physical DescriptionSolid

Physicochemical properties

LogP
-0.57 · -0.570 (est)
NCI Dictionary of Cancer Terms
-5 · methyl-5-aminolevulinate
FDA UNII
585 NM85KYM · 585NM85KYM

Chemistry & industry

Pharmacology

ATC Code · 3 items

L01XD03

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Pharmacodynamics · 1 item

After topical application of methyl aminolevulinate, porphyrins will accumulate intracellularly in the treated skin lesions. The intracellular porphyrins (including PpIX) are photoactive, fluorescing compounds and, upon light activation in the presence of oxygen, singlet oxygen is formed which causes damage to cellular compartments, in particular the mitochondria. Light activation of accumulated porphyrins leads to a photochemical reaction and thereby phototoxicity to the light-exposed target cells.

Mechanism of Action · 1 item

Photosensitization following application of methyl aminolevulinate cream occurs through the metabolic conversion of methyl aminolevulinate (prodrug) to photoactive porphyrins (PAP), which accumulates in the skin lesions to which the cream has been applied. When exposed to light of appropriate wavelength and energy, the accumulated photoactive porphyrins produce a photodynamic reaction, resulting in a cytotoxic process dependent upon the simultaneous presence of oxygen. The absorption of light results in an excited state of porphyrin molecules, and subsequent spin transfer from photoactive porphyrins to molecular oxygen generates singlet oxygen, which can further react to form superoxide and hydroxyl radicals.

FDA Pharmacological Classification · 5 items

585NM85KYM

METHYL AMINOLEVULINATE

Established Pharmacologic Class [EPC] - Porphyrin Precursor

Chemical Structure [CS] - Porphyrinogens

Methyl aminolevulinate is a Porphyrin Precursor.

MeSH Pharmacological Classification · 1 item

Drugs that are pharmacologically inactive but when exposed to ultraviolet radiation or sunlight are converted to their active metabolite to produce a beneficial reaction affecting the diseased tissue. These compounds can be administered topically or systemically and have been used therapeutically to treat psoriasis and various types of neoplasms.

Related reactions

5 records
New reaction record
HRID 297837 reaction equation
HRID 297837As product
HRID 806085 reaction equation
HRID 806085As product
HRID 1072399 reaction equation
HRID 1072399As reactant
HRID 1543056 reaction equation
HRID 1543056As reactant
HRID 1560255 reaction equation
HRID 1560255As productAs reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesChemistry & industryRelated reactionsCompound notes
Absorption, Distribution and ExcretionIn vitro, after 24 hours the mean cumulative absorption through human skin was 0.26% of the administered dose.
Cellular LocationsMembrane

Applications

UsesMethyl aminolevulinate is an agent used as a sensitizer in photodynamic therapy (PDT). Methyl aminolevulinate is a proagent that can be metabolized to Protoporphyrin IX[1].

Additional notes · 1 item

DefinitionChEBI: The methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydro hloride salt) results in an accumulation of protoporphyrin IX in the skin lesions to which the cream has been applied. Subsequent illumination with red light results in the generation of toxic singlet oxygen that destroys cell membranes and thereby kills t e tumour cells.